Currently, after several years of research, a vaccine that could treat type 1 diabetes, a vaccine called Diamyd that is undergoing Phase 2 tests and has been successful, is being tested in humans, with expected final results by the second half of 2020.
Type 1 diabetes is an autoimmune disease in which the immune system reacts against the body itself, destroying the beta cells of the pancreas, responsible for the production of insulin, a hormone that regulates the absorption of sugar from the bloodstream within the body.Be aware of the symptoms of type 1 diabetes.
- The vaccine.
- Which is injected into the lymph node.
- Aims to reduce the sensitivity of the immune system.
- In order to preserve the beta cells of the pancreas still functional and allow them to continue producing insulin.
Glutamic acid derboxylase, also known as GAD65, is an endogenous protein that is expressed by pancreatic beta cells and which, in type 1 diabetes, is identified by the immune system as dangerous; in these cases, the immune system reacts against this protein, destroying the beta cells of the pancreas, gradually reducing insulin production.
The Diamyd vaccine contains a glutamic acid decroxylasse protein in its composition, which works by reducing the sensitivity of the immune system, preserving insulin-producing cells that remain functional, allowing them to continue producing insulin, even in small amounts.
Diamyd is a vaccine that should be given directly into the lymph node in order to preserve the endogenous insulin produced.The final results of the study are expected for the second half of 2020.
Learn about other treatments being studied and promise to cure diabetes.